Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 4/20 | 0.69 |
| ▸ | POLA1 | P09884 | 1/20 | 0.69 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | INPP5D | Q92835 | 1/20 | 0.54 |
| ▸ | VDR | P11473 | 3/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | ST6GAL1 | P15907 | 2/20 | 0.52 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.51 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19722249 | 1.00 | CDC25A (0.69) | CDC25APOLA1FOLH1CYP2D6CYP2C19 | |
| SCHEMBL21298981 | 0.91 | CDC25A (0.66) | CDC25APOLA1FOLH1CYP2D6CYP2C19 | |
| SCHEMBL21322100 | 0.91 | CDC25A (0.66) | CDC25APOLA1FOLH1CYP2D6CYP2C19 | |
| SCHEMBL19755104 | 0.91 | CDC25A (0.66) | CDC25APOLA1FOLH1CYP2D6CYP2C19 | |
| SCHEMBL19722604 | 0.91 | CDC25A (0.66) | CDC25APOLA1FOLH1CYP2D6CYP2C19 | |
| SCHEMBL23635620 | 0.90 | CDC25A (0.67) | CDC25APOLA1FOLH1CYP2D6CYP2C19 | |
| SCHEMBL20882353 | 0.90 | CDC25A (0.67) | CDC25APOLA1FOLH1CYP2D6CYP2C19 | |
| SCHEMBL19856318 | 0.90 | CDC25A (0.67) | CDC25APOLA1FOLH1CYP2D6CYP2C19 | |
| SCHEMBL21398485 | 0.90 | CDC25A (0.67) | CDC25APOLA1FOLH1CYP2D6CYP2C19 | |
| SCHEMBL19854980 | 0.90 | CDC25A (0.55) | CDC25APOLA1FOLH1CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214615-A1 | LIQUID CRYSTAL DISPLAY DEVICE AND DISPLAY UNIT | JNC CORPORATION (JP) | 2021-07-15 | — | — | US | disclosed |
| US-10392339-B2 | Polymerizable polar compound, liquid crystal composition, and liquid crystal display element | JNC CORPORATION (JP) | 2019-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392339-B2 | Polymerizable polar compound, liquid crystal composition, and liquid crystal display element | SP1, HVCN1, CXCR1 | CDC25A 105/4885POLA1 1041/4885FOLH1 4469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.